ABMSCs have been experimentally tried in animal models (2.1-2.4) and human studies (3) in treating RDDs by intravitreal injection. NCRM has been working on undifferentiated expansion of ABMSC with specificity to CD34+ cells towards further improvising the results reported in earlier studies
(1) Sheriff AK, Senthilkumar R, Farzana BL, Manjunath S, Mohanashankar M, Naveen AT, Natarajan S, Mori Y, Yoshioka H, Abraham S , "Expansion and molecular characterization of human cadaver Retinal Pigment Epithelial Cells". First Annual Meeting of SCRFI and International Conference on Stem Cell Research, Bangalore, India; 29th Jan - 1st Feb, 2007
(2.1) Harris JR, Brown GA, Jorgensen M, Kaushal S, Ellis EA, Grant MB, Scott EW. “Bone marrow-derived cells home to and regenerate retinal pigment epithelium after injury”. Invest Ophthalmol Vis Sci. 2006 ;47(5):2108-13.
(2.2) Otani A, Kinder K, Ewalt K, Otero FJ, Schimmel P, Friedlander M. “Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis”. Nat Med. 2002;8(9):1004-10.
(2.3) Otani A, Dorrell MI, Kinder K, Moreno SK, Nusinowitz S, Banin E, Heckenlively J, Friedlander M. “Rescue of retinal degeneration by intravitreally injected adult bone marrow-derived lineage-negative hematopoietic stem cells”. J Clin Invest. 2004;114(6):765-74.
(2.4) Atmaca-Sonmez P, Li Y, Yamauchi Y, Schanie CL, Ildstad ST, Kaplan HJ, Enzmann V. “Systemically transferred hematopoietic stem cells home to the subretinal space and express RPE-65 in a mouse model of retinal pigment epithelium damage”. Exp Eye Res. 2006; 83(5):1295-302
(3) Kumar A, Kumar Pahwa A, Tandon R, Kumar L, Mohanty S. “Use of Autologous Bone Marrow Derived Stem Cells for Rehabilitation of Patients with Dry Age Related Macular Degeneration and Retinitis Pigmentosa: Phase-1 Clinical Trial”. Ind J of Med. Paediatric Onc 2005.